Precipio Q4 2023 Earnings Report

Precipio EPS Results

• Actual EPS: -$0.41
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Precipio Revenue Results

• Actual Revenue: $4.33 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Precipio Announcement Details

• Quarter: Q4 2023
• Date: 3/29/2024
• Time: N/A
• Conference Call Date: Friday, March 29, 2024
• Conference Call Time: 8:00AM ET

Precipio (NASDAQ:PRPO) is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput. This platform is complemented by a suite of proprietary reagents and staining kits specifically engineered for hematopathology applications. In addition, Precipio provides specialized molecular assays—including cytogenetics, flow cytometry panels and next-generation sequencing tests—that enable comprehensive profiling of genetic and phenotypic markers in patient samples.

Precipio operates through two primary divisions: a laboratory services arm that performs diagnostic testing on patient specimens using its proprietary technologies, and a product division that markets instruments, reagents and software to hospitals, commercial laboratories and academic research centers. Headquartered in Pittsburgh, Pennsylvania, the company has established strategic partnerships and distribution channels within the United States and is exploring opportunities to expand its presence in select international markets.

Under the leadership of President and CEO Michael Q. McNamara, Precipio has pursued both in-house development and collaborative agreements with academic institutions and industry players to accelerate its product pipeline. Since its founding, the company has remained committed to leveraging innovations in digital pathology and molecular diagnostics, positioning itself as a contributor to the evolving precision medicine paradigm in hematologic oncology.